MAM
SAGE icon

Martingale Asset Management’s Sage Therapeutics SAGE Stock Holding History

Martingale Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-62,343
Closed -$569K – 829
2025
Q2 		$569K Sell
62,343
-10,914
-15% -$80.3K 0.01% 593
2025
Q1 		$582K Sell
73,257
-6,926
-9% -$50.7K 0.01% 573
2024
Q4 		$435K Buy
80,183
+33,106
+70% +$202K 0.01% 630
2024
Q3 		$340K Buy
47,077
+16,717
+55% +$153K 0.01% 693
2024
Q2 		$330K Buy
30,360
+11,216
+59% +$144K 0.01% 680
2024
Q1 		$359K Buy
19,144
+1,000
+6% +$23.1K 0.01% 679
2023
Q4 		$393K Buy
+18,144
New +$360K 0.01% 654
2023
Q3 		– Sell
-16,914
Closed -$795K – 840
2023
Q2 		$795K Hold
16,914
– – 0.02% 507
2023
Q1 		$710K Buy
+16,914
New +$727K 0.01% 532

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Martingale Asset Management's SAGE Position: Q3 2025 in Review

Martingale Asset Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 62,343 shares — an estimated $569K sold.

Martingale Asset Management first reported a position in SAGE in Q1 2023 and held it in 9 quarters. The position peaked at $795K in Q2 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Martingale Asset Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Martingale Asset Management sold 62,343 Sage Therapeutics shares in Q3 2025, an estimated $569K.
  • Martingale Asset Management first reported a position in Sage Therapeutics in Q1 2023 and held it in 9 quarters.
  • Martingale Asset Management's Sage Therapeutics position peaked at $795K in Q2 2023.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Martingale Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.